Panther Biotechnology announces acquisition of Alchemia Oncology

Published: 3-Jul-2015
Research & Development Finance

The acquisition further strengthens Panther's drug development and platform technology portfolio


Panther Biotechnology, a biotechnology company specialising in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, has entered into an agreement to acquire Alchemia Oncology, a wholly owned subsidiary of Alchemia, an Australian biotechnology company listed on the Australian Stock Exchange (ACL).

Alchemia Oncology has a robust collection of clinical and preclinical oncology assets, which include the HyACT drug delivery platform, a portfolio of targeted therapeutics that are designed to exploit the unique structure and inherent biological properties of hyaluronic acid.

Drug candidates in the portfolio range from preclinical through to phase III. Panther intends to file a new phase III protocol for an open IND with the FDA for HA-Irinotecan in 2015, in addition to advancing the other phase II and phase Ib clinical drug candidates.

‘The acquisition of Alchemia Oncology further strengthens our drug development and platform technology portfolio,’ stated Evan Levine, Chief Executive Officer of Panther. ‘This milestone transaction results from intensive mutual due diligence and a commitment to patient care in which chemotherapy results can improve patient response and survival.’

‘Alchemia Oncology has spent more than 15 years and US$70m to develop the HyACT technology platform and clinical drug candidates, and we are very pleased to have secured the commitment of Panther to raise the necessary funds to continue the clinical development of HyACT,’ stated Tracie Ramsdale, Executive Director of Alchemia.

  • Companies:
  • Alchemia
  • Panther Biotechnology
See more

You may also like

Drug Delivery

Panther to acquire technology assets of Faulk Pharmaceuticals

Read more
Transaction expands Panther's pipeline to include multiple new drug candidates in cancer and antiviral diseases

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Drug Delivery

Panther to acquire technology assets of Faulk Pharmaceuticals

Transaction expands Panther's pipeline to include multiple new drug candidates in cancer and antiviral diseases
Regulatory

Dr. Reddy’s announces US FDA approval of Fondaparinux

Dr. Reddy’s will manufacture the drug under licence using an Alchemia process
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now